Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil 5mg post AEEP
NCT07466030Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) comparing Daily tadalafil 5 mg user with Placebo (2 arms). Primary endpoint: Proportion of patients achieving stress urine incontinence at 12 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tadalafil
03
Conditions
lower urinary tract symptoms (LUTS)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07466030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466030.